Questcor Pharmaceuticals — Q2 2011 Earnings Presentation
16 slides from Questcor Pharmaceuticals's earnings presentation, Jul 29, 2011
Slide 1: Second Quarter Conference Call
NASDAQ: QCOR Second Quarter Conference Call NASDAQ: QCOR Second Quarter Conference Call Exhibit 99.3
Slide 2: Conference Call Logistics
2 • The release, presentation slides, and replay webcast are available at www.questcor.com . The presentation slides and replay webcast will be accessible in the "Investor Relations" section under "Events & Presentations." • To access an audio replay of the call: – U.S.: 800-406-7325 – International
Slide 3: Safe Harbor Statement
3 Safe Harbor Statement Note: Except for the historical information contained herein, these slides contain forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In
Slide 4: QCOR Had a Record Second Quarter
4 • 751 paid MS scripts – Up 147% YOY – Up 48% sequentially • 45 paid NS scripts – Much better than expected • Record financial performance – 2,430 vials – $46.0M in net sales – $0.21 EPS • Lupus announced as next vertical market QCOR Had a Record Second Quarter • 751 paid MS scripts – Up 147% YOY –
Slide 5: MS Sales - Record of Consistent Growth
5 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which i
Slide 6: Strong Correlation-Sales Calls vs. Rxs
6 Strong Correlation-Sales Calls vs. Rxs *MS call data approximate 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 10,000 MS Paid/Shipped RX's MS Calls
Slide 7: NS Sales – Off to a Good Start
7 NS Sales – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the fo
Slide 8: Systemic Lupus Erythematosus (Lupus)
8 • High unmet need • Serious Health risk if unsuccessfully treated • Difficult to treat • Multiple on-label indications for Acthar – Exacerbations – Maintenance therapy – Lupus nephritis • Large patient population Systemic Lupus Erythematosus (Lupus) • High unmet need • Serious Health risk if unsuc
Slide 9: MS Sales - Record of Consistent Growth
9 MS Sales - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which i
Slide 10: NS Sales – Off to a Good Start
10 NS Sales – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the f
Slide 11: Total Acthar Sales Force
11 • Specialty Sales Force – Main focus on MS (~80%), 15% on NS, 5% on IS – 77 representatives, 13 regional managers, one national director • Nephrology Sales Force – Focus 100% on Nephrotic syndrome – 28 representatives, 4 regional managers, one national director • Combined Forces will be calling o
Slide 12: NS Phase IV Company Sponsored Study
12 • Treatment Resistant Idiopathic Membranous Nephropathy • Dose response trial – Randomized, double blinded 3 arm study with 2 different dosage regimens of Acthar and placebo – n=84 (approximate), 35 centers (approximate) – Endpoint is reduction of proteinuria • Trial milestones – First patient do
Slide 13: Q2-2011 Financial Results
13 Q2-2011 Financial Results Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 46.0 94% $20.4 $0.21 $28.3 93% $14.3 $0.14 Q2-2011 Q2-2010 Record Sales (up 62%) and Solid Earnings (EPS up 50%) Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 46.0 9
Slide 14: Questcor is Cash Flow Positive
14 Questcor is Cash Flow Positive Cash / ST Investments Accounts Receivable $144M* $20M 7/15/11 *After return of $78 million of cash to shareholders through share repurchases. Cash / ST Investments Accounts Receivable $144M* $20M 7/15/11
Slide 15: Questcor had an excellent quarter
Questcor had an excellent quarter Acthar has sustainable competitive advantages : Focus on substantial growth in MS and NS sales Newvertical market— Lupus Market sizes have good growth potential Potential for other vertical markets (& QUESTCOR’
Slide 16: Second Quarter Conference Call
NASDAQ: QCOR Second Quarter Conference Call NASDAQ: QCOR Second Quarter Conference Call
Questcor Pharmaceuticals — Q2 2011 Earnings Presentation on 6ix